Global CD233 Inhibitors Trials Intelligence Report Highlights:
- Global CD233 Inhibitors Market Dynamics
- Clinical Approaches to Target CD233 Inhibitors
- Role of CD233 Inhibitors in Cancer, Autoimmune Disorders
- Number of CD233 Inhibitors Drug In Trials
- CD233 Inhibitors Approved Patent Insight
- CD233 Inhibitors Trials By Phase, Company, Country, Indication
- Company Agreement/Partnership/Deals For Ongoing Trials
- Global CD233 Inhibitor Market Future Outlook
For Report Sample Contact email@example.com
The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1 mAbs has paved the way to a new era of anticancer therapy changing the therapeutic scenario in a number of tumor settings. However, clinical benefit is still limited to a subset of patients, which is likely due to the heterogeneity of the cancer immunogenic profile during growth and dissemination, and acquisition of resistance mechanisms. Further, co-administration of PD-1/PD-L1 and CTLA-4 inhibitor has strengthened the evidence that the combination of drugs targeting different immune checkpoint regulatory pathways is a feasible approach to improve treatment efficacy and potentially delay or prevent tumor resistance.
The better understanding about tumor microenvironment and has led to identification of several co-stimulatory receptors including CD223, TIM-3, and TIGIT, which display functional redundancy with CTLA-4 and PD-1/PD-L1 axes. Among all, CD223 or lymphocyte activation gene-3 has gained considerable interest among research institutions and pharmaceutical sectors. CD223 is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. In addition to this, these molecules are also expressed in tumor micro environment which makes them potential target in cancer immunotherapy.
The identification of novel immunoreceptor has surged the development of novel CD223 targeting drugs in preclinical and clinical development. Several potential inhibitors including Relatlimab, IMP321, LAG525, MGD013, MK4280, FS118, and other are present in early phase of clinical development and will transform the cancer immunotherapy in 4-5 years. Recently in 2021, Relatlimab has received priority review from US FDA and it is expected to enter the market by 2022. The entrance of these drugs in the market by next year is expected to transform the overall cancer therapeutics market. It is expected that the market will be inclined more towards immunotherapy in coming years which is mainly due to their ability to overcome PD-1/PD-L1 drug resistance in cancer patients.
Beyond the inhibitory activity of CD223 on different types of cancers, CD223 may also be necessary to negatively regulate autoimmunity in many disease-prone environments. For instance, loss of LAG-3 substantially can accelerate type 1 diabetes in Non-Obese Diabetic (NOD) mice with 100% incidence. LAG-3 deficient mice can exhibit increased antigen-reactive CD4+ and CD8+ T cells infiltration in the islets, accompanied by invasive and rapid insulitis. Therefore, researchers are also expanding their knowledge of targeting CD223 signalling pathways as an alternative approach to manage other therapeutic indications, which is further boosting the market growth.
The growing burden of critical diseases such as cancer, leukemia, lymphoma, and muscular degeneration are the major factors that boost the adoption of CD223 targeting drugs among the global population. The growing adoption of technological advancements in the field of biopharmaceutical and rising consumer awareness regarding the safety of the CD223 targeted therapeutics will also be driving the market growth during the forecast period. In addition, the increased efficiency of the novel CD223 targeted drugs to treat such deadly diseases with minimal side effects is also major driving factor of the market.
US is expected to be the leading consumer of the CD223 targeted therapeutics owing to the increased adoption rate and higher demand for the advanced and innovative products. The rapidly booming biologics industry is a significant factor that propels the growth of the targeted therapeutics market in US. Further, the presence of numerous CMOs and CROs along with the various biopharmaceutical companies together contributes towards the market development. Moreover, the rising geriatric population, increased disposable income, presence of high-end technologies and developed healthcare infrastructure, and rising demand for the biologic drugs is driving the growth of the targeted therapeutics in US.